{"company": {"org_id": "Q01BAB87C7", "org_name_cn": "诺诚健华医药有限公司", "org_short_name_cn": "诺诚健华", "org_name_en": "Innocare Pharma Limited", "org_short_name_en": "InnoCare", "main_operation_business": "创新药的研发、生产及商业化。", "operating_scope": null, "district_encode": "013002", "org_cn_introduction": "诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。", "legal_representative": null, "general_manager": "崔霁松", "secretary": null, "established_date": 1446480000000, "reg_asset": 3529.29, "staff_num": 1146, "telephone": "86-10-66609913", "postcode": "102206", "fax": "86-10-60702992", "email": "info@innocarepharma.com;ir@innocarepharma.com", "org_website": "www.innocarepharma.com", "reg_address_cn": "Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands", "reg_address_en": "89 Nexus Way\r\nCamana Bay\r\nGrand Cayman\r\nKY1-9009\r\nCayman Islands", "office_address_cn": "北京市昌平区中关村生命科学园生命园路8号院8号楼", "office_address_en": "Building 8\r\nNo. 8 Life Science Park Road\r\nZhongguancun Life Science Park\r\nChangping District\r\nBeijing\r\nPRC", "currency_encode": "019003", "currency": "USD", "listed_date": 1663689600000, "provincial_name": null, "actual_controller": "", "classi_name": "外资企业", "pre_name_cn": null, "chairman": "崔霁松", "executives_nums": 9, "actual_issue_vol": 264648217.0, "issue_price": 11.03, "actual_rc_net_amt": 2778815600.0, "pe_after_issuing": null, "online_success_rate_of_issue": 0.0601096, "affiliate_industry": {"ind_code": "BK0042", "ind_name": "生物制品"}}}